Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Jesper Kofoed Damm; Sandra Gordon; Mats Ehinger; Mats Jerkeman; Urban Gullberg; Anne Hultquist; Kristina Drott

doi:10.1186/2162-3619-4-4

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Jesper Kofoed Damm, Sandra Gordon, Mats Ehinger, Mats Jerkeman, Urban Gullberg, Anne Hultquist, Kristina Drott

Research output: Contribution to journal › Article › peer-review

264 Downloads (Pure)

Abstract

Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.

Original language	English
Journal	Experimental hematology & oncology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1186/2162-3619-4-4
Publication status	Published - 2015

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Division of Clinical Genetics (013022003), Stem Cell Center (013022011), Oncology, Kamprad Lab (013230901), Pathology, (Lund) (013030000), Hematopoietic Stem Cell Laboratory (013022012)

Subject classification (UKÄ)

Hematology
Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/2162-3619-4-4

BMC_Damm_et_al

http://www.ncbi.nlm.nih.gov/pubmed/25973343?dopt=Abstract

Cite this

@article{33f0e83e3a8645b6941825dc13987248,

title = "Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.",

abstract = "Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.",

author = "{Kofoed Damm}, Jesper and Sandra Gordon and Mats Ehinger and Mats Jerkeman and Urban Gullberg and Anne Hultquist and Kristina Drott",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Division of Clinical Genetics (013022003), Stem Cell Center (013022011), Oncology, Kamprad Lab (013230901), Pathology, (Lund) (013030000), Hematopoietic Stem Cell Laboratory (013022012)",

year = "2015",

doi = "10.1186/2162-3619-4-4",

language = "English",

volume = "4",

journal = "Experimental hematology & oncology",

issn = "2162-3619",

publisher = "BioMed Central (BMC)",

number = "4",

}

TY - JOUR

T1 - Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

AU - Kofoed Damm, Jesper

AU - Gordon, Sandra

AU - Ehinger, Mats

AU - Jerkeman, Mats

AU - Gullberg, Urban

AU - Hultquist, Anne

AU - Drott, Kristina

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Division of Clinical Genetics (013022003), Stem Cell Center (013022011), Oncology, Kamprad Lab (013230901), Pathology, (Lund) (013030000), Hematopoietic Stem Cell Laboratory (013022012)

PY - 2015

Y1 - 2015

N2 - Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.

AB - Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.

U2 - 10.1186/2162-3619-4-4

DO - 10.1186/2162-3619-4-4

M3 - Article

C2 - 25973343

SN - 2162-3619

VL - 4

JO - Experimental hematology & oncology

JF - Experimental hematology & oncology

IS - 4

ER -

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Abstract

Bibliographical note

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this